Navigation Links
Roka Bioscience Completes $20 Million Series C Financing
Date:7/28/2011

WARREN, N.J., July 28, 2011 /PRNewswire/ -- Roka Bioscience, Inc. announced today that it recently completed a Series C round of equity financing, raising $20 million in new capital. The financing brings the total amount raised to $57.2 million since the company's formation in September 2009. The investor syndicate included participation from all existing investors including OrbiMed Advisors, New Enterprise Associates, Inc., TPG Biotech and Gen-Probe Incorporated (NASDAQ: GPRO).

"We are very pleased with the continued support of our existing investors and their confidence in our ability to become a leader in providing innovative solutions based on molecular technologies for the industrial markets," said Paul Thomas, CEO and President of Roka Bioscience. "We are on track to commercialize our first molecular assay for food safety testing later this year," he added.

Roka Bioscience was established in September 2009 through a spin-off of Gen-Probe's industrial testing assets and technology into a new independent company focused on developing rapid, highly accurate molecular assays for food safety testing and other industrial applications. Roka's nucleic acid tests will be based on proven technologies and instrument platforms with exclusive licensing rights from Gen-Probe. Eighteen former Gen-Probe employees with expertise in industrial fields joined Roka at the time of the spin-off. Today the company has 75 employees.

"Combining a proven technology platform with an experienced management team and a large market opportunity is a recipe for success. We believe Roka has all three," said Jonathan Silverstein, General Partner, OrbiMed Advisors.

About Roka Bioscience

Roka Bioscience is a privately held company focused on developing and commercializing innovative solutions based on molecular technologies for the industrial markets. The company's scientific platform is based on proven, proprietary technologies used widely in clinical diagnostic testing and now being introduced into food safety and other industrial markets. Roka's current product line provides food safety professionals with a fully-automated molecular pathogen detection solution that delivers rapid, accurate results and improved laboratory efficiencies. For more information, visit www.rokabio.com.

Contact:  
Steve Sobieski, Chief Financial Officer
(908) 605-4621   ssobieski@rokabio.com


'/>"/>
SOURCE Roka Bioscience
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
(Date:5/3/2016)... -- Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling ... ... ... ... ...
Breaking Medicine Technology:
(Date:5/4/2016)... NJ (PRWEB) , ... May 04, 2016 , ... ... pharmacists and the pharmacy industry, today announced that it was chosen as the ... Alliance (APPA) Industry Awards . The awards acknowledge the hard work and dedication ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... multi-function small and compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL ... model NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 batteries to ...
(Date:5/4/2016)... ... May 04, 2016 , ... AudioEducator is ... compliance. In upcoming months, AudioEducator has lined up some informative training session for ... to give complete compliance know-how and practical, easy-to-apply advice. , On Thursday, May ...
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. ... also called UTIs, have plagued people since the beginning of recorded medical history, ... bladder infections every year. It's not just a matter of inconvenience; bladder infections cost ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... a powerful cellular therapy software application that helps blood and marrow transplant (BMT) ... Since Transtem’s initial launch, Mediware has continued to enhance core application features. These ...
Breaking Medicine News(10 mins):